Logo

American Heart Association

  15
  0


Final ID: MP2399

FibriCheck Detection Capabilities for Atrial Fibrillation: A Multicenter Validation Study

Abstract Body (Do not enter title and authors here): Background: Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity, mortality, and healthcare spending. Despite medical advances, AF remains underdiagnosed and undertreated, leading to preventable complications. FibriCheck © [Qompium NV, Hasselt, Belgium] is a medical analysis platform that uses an end-to-end algorithm to detect AF based on photoplethysmography (PPG) signals recorded on consumer smartphones.
Purpose: The study aimed to validate FibriCheck in a large, multi-center and multi-national cohort on ten popular smartphone devices.
Methods: A total of 236 patients were recruited from five independent, large academic centers in the United States and Europe. The FibriCheck system incorporates several convolutional neural networks to detect individual heartbeats, estimate average heart rate, and classify the rhythm based on PPG signals. Classification is verified by a FibriCheck technician. Classification performance was compared to the standard 12-lead electrocardiogram in the study population. Performance was assessed across clinical subgroups and smartphone devices.
Results: FibriCheck demonstrated high overall accuracy and reliability in detecting AF without technician verification: accuracy 98.5% (95% CI: 98.0%-99.0%); sensitivity 96.3% (95% CI: 94.4%-97.7%); specificity 99.3% (95% CI: 98.8%-99.7%); positive predictive value 98.0% (95% CI: 96.5%-98.9%); negative predictive value 99.8% (95% CI: 99.6%-99.9%). Performance was not affected by smartphone device or the presence or absence of comorbid heart failure, vascular disease, hypertension, diabetes, or stroke. Sensitivity was reduced in those with darker skin tone and higher BMI, but this was mitigated by technician verification.
Conclusions: The study confirms the high accuracy, sensitivity, and specificity of the FibriCheck algorithm in detecting AF across various smartphone models and clinical subgroups. These findings support the use of FibriCheck as a reliable, low-cost, and easily accessible tool for AF detection in a diverse patient population.
  • Sollee, John  ( Feinberg School of Medicine, Northwestern University , Chicago , Illinois , United States )
  • Nuyens, Dieter  ( Hospital Oost Limburg , Genk , Belgium )
  • Rivero-ayerza, Maximo  ( Hospital Oost Limburg , Genk , Belgium )
  • Van Herendael, Hugo  ( Hospital Oost Limburg , Genk , Belgium )
  • Thomas, James  ( Feinberg School of Medicine, Northwestern University , Chicago , Illinois , United States )
  • Cheema, Baljash  ( Feinberg School of Medicine, Northwestern University , Chicago , Illinois , United States )
  • Slotwiner, David  ( New York Presbyterian Queens, Weill Cornell Medical College , New York , New York , United States )
  • Volodarskiy, Alexander  ( New York Presbyterian Queens, Weill Cornell Medical College , New York , New York , United States )
  • Desteghe, Lien  ( Antwerp University Hospital , Antwerp , Belgium )
  • Buyck, Christophe  ( Antwerp University Hospital , Antwerp , Belgium )
  • Heidbuchel, Hein  ( Faculty of Medicine and Life Sciences, Hasselt University , Hasselt , Belgium )
  • Stavrakis, Stavros  ( University of Oklahoma Health Sciences Center , Oklahoma City , Oklahoma , United States )
  • Pison, Laurent  ( Hospital Oost Limburg , Genk , Belgium )
  • Author Disclosures:
    John Sollee: DO NOT have relevant financial relationships | Dieter Nuyens: No Answer | Maximo Rivero-Ayerza: No Answer | Hugo Van Herendael: No Answer | James Thomas: No Answer | Baljash Cheema: No Answer | David Slotwiner: No Answer | Alexander Volodarskiy: DO NOT have relevant financial relationships | Lien Desteghe: No Answer | Christophe Buyck: DO NOT have relevant financial relationships | Hein Heidbuchel: DO have relevant financial relationships ; Speaker:Biotronik:Past (completed) ; Other (please indicate in the box next to the company name):Pfizer-BMS unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Novartis unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Novo Nordisk unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Viatris Pharmaceuticals unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Daiichi-Sankyo unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Boston Scientific unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Biosense-Webster unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Boehringer-Ingelheim unconditional research grants through the University of Antwerp and/or the University of Hasselt:Active (exists now) ; Other (please indicate in the box next to the company name):Bayer (unconditional research grants through the University of Antwerp and/or the University of Hasselt):Active (exists now) ; Other (please indicate in the box next to the company name):Abbott (unconditional research grants through the University of Antwerp and/or the University of Hasselt):Active (exists now) ; Speaker:Viatris:Past (completed) ; Speaker:ESC:Past (completed) ; Speaker:IZIDOK:Past (completed) ; Speaker:Daiichi-Sankyo:Past (completed) | Stavros Stavrakis: DO NOT have relevant financial relationships | Laurent Pison: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Clinical Electrophys: Diagnosis and Risk Stratification

Monday, 11/10/2025 , 10:45AM - 11:45AM

Moderated Digital Poster Session

More abstracts on this topic:
1-Year Outcomes After Cardioversion With and Without Anticoagulation in Patients With Left Atrial Appendage Occlusion: A Propensity-Matched Analysis

Thangjui Sittinun, Trongtorsak Angkawipa, Kewcharoen Jakrin, Thyagaturu Harshith, Watson Hangyu, Mensah Samuel, Balla Sudarshan, Navaravong Leenhapong

A Deep Learning Topic Analysis Approach for Enhancing Risk Assessment in Heart Failure Using Unstructured Clinical Notes

Adejumo Philip, Pedroso Aline, Khera Rohan

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available